Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer
Chunyan Gu-Trantien, Edoardo Migliori, Laurence Buisseret, Alexandre de Wind, Sylvain Brohée, Soizic Garaud, Grégory Noël, Vu Luan Dang Chi, Jean-Nicolas Lodewyckx, Céline Naveaux, Hugues Duvillier, Stanislas Goriely, Denis Larsimont, Karen Willard-Gallo
Chunyan Gu-Trantien, Edoardo Migliori, Laurence Buisseret, Alexandre de Wind, Sylvain Brohée, Soizic Garaud, Grégory Noël, Vu Luan Dang Chi, Jean-Nicolas Lodewyckx, Céline Naveaux, Hugues Duvillier, Stanislas Goriely, Denis Larsimont, Karen Willard-Gallo
View: Text | PDF
Research Article Immunology Oncology

CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer

  • Text
  • PDF
Abstract

T follicular helper cells (TFH cells) are important regulators of antigen-specific B cell responses. The B cell chemoattractant CXCL13 has recently been linked with TFH cell infiltration and improved survival in human cancer. Although human TFH cells can produce CXCL13, their immune functions are currently unknown. This study presents data from human breast cancer, advocating a role for tumor-infiltrating CXCL13-producing (CXCR5–) TFH cells, here named TFHX13 cells, in promoting local memory B cell differentiation. TFHX13 cells potentially trigger tertiary lymphoid structure formation and thereby generate germinal center B cell responses at the tumor site. Follicular DCs are not potent CXCL13 producers in breast tumor tissues. We used the TFH cell markers PD-1 and ICOS to identify distinct effector and regulatory CD4+ T cell subpopulations in breast tumors. TFHX13 cells are an important component of the PD-1hiICOSint effector subpopulation and coexpanded with PD-1intICOShiFOXP3hi Tregs. IL2 deprivation induces CXCL13 expression in vitro with a synergistic effect from TGFβ1, providing insight into TFHX13 cell differentiation in response to Treg accumulation, similar to conventional TFH cell responses. Our data suggest that human TFHX13 cell differentiation may be a key factor in converting Treg-mediated immune suppression to de novo activation of adaptive antitumor humoral responses in the chronic inflammatory breast cancer microenvironment.

Authors

Chunyan Gu-Trantien, Edoardo Migliori, Laurence Buisseret, Alexandre de Wind, Sylvain Brohée, Soizic Garaud, Grégory Noël, Vu Luan Dang Chi, Jean-Nicolas Lodewyckx, Céline Naveaux, Hugues Duvillier, Stanislas Goriely, Denis Larsimont, Karen Willard-Gallo

×

Figure 1

CXCL13 is principally produced by CD4+ tumor-infiltrating lymphocytes (TIL) in human breast cancer (BC).

Options: View larger image (or click on image) Download as PowerPoint
CXCL13 is principally produced by CD4+ tumor-infiltrating lymphocytes (T...
(A) Kaplan-Meier analysis of disease-free survival for 60 BC patients stratified on CXCL13 gene expression (qPCR) or FDC network positivity (CD23hi IHC staining). (B and C) Immunofluorescence (IF) staining of representative BC tissue sections showing CXCL13+ TIL (red), CD20+ B-TIL (green), and CD21hi FDC (blue) expression in tertiary lymphoid structures (TLS) containing germinal centers (GC); the zoomed areas (right) are defined by white boxes. In some images, the contrast was enhanced by turning down DAPI (gray) intensity. White and yellow scale bars: 100 μm and 10 μm, respectively (B, C, and G). (D) Flow cytometric analysis showing CXCL13 expression in a representative fresh BC homogenate (dot plots) or as the % CXCL13+ TIL within the lymphocyte gate for 38 BC (graph). (E) Relative proportions of CD4+ or CD8+ T cells in CXCL13+ TIL shown for 2 representative BC (dot plots) or for 11–18 BC patients (bar graph). (F) % CXCL13+ in CD4+ and CD8+ TIL pairs from 24 BC patients; paired 2-tailed student t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (G) IF staining of representative BC tissue sections showing CXCL13+ (red), CD20+ (green), and either CD4+ or CD8+ (blue) TIL; arrows indicate CXCL13+CD4– (white) or CXCL13+CD8+ (yellow) TIL.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts